Edwards Lifesciences — Apr 23, 2026 release

Highlights and Outlook • Q1 sales grew 16.7% to $1.65 billion 1 , constant currency 2 sales grew 12.7% • Q1 TAVR sales grew 14.4% to $1.20 billion 1 ; constant currency 2 sales grew 11.0% • Q1 TMTT sales of $173 million 1,3 , driven by repair and replacement therapies • Q1 EPS of $0.66 1 ; adjusted 2 EPS of $0.78 1 • Raising FY 2026 constant currency 2 sales growth guidance to 9% to 11% from 8% to 10% • Raising FY 2026 adjusted 2 EPS guidance midpoint; new range of $2.95 to $3.05 from $2.90 to $3.05 • Renewed clinical focus on proactive disease management with differentiated SAPIEN TAVR • Completed $500 million Accelerated Share Repurchase “Building on a year in 2025 marked by solid financial performance and strategic progress, we delivered another strong quarter in Q1, achieving 12.7% sales growth, which reflects the impact and durability of our focused strategy. We remain dedicated to solving large, urgent and complex patient needs and pursuing unique opportunities to innovate and lead in structural heart disease,” said Bernard Zovighian, Edwards’ CEO. “Based on our first quarter performance, we are raising our financial guidance for 2026. We continue to pursue additional meaningful growth opportunities across our portfolio, and our financial strength and strategic clarity give us confidence in the future.” Transcatheter Aortic Valve Replacement (TAVR) In the first quarter, the company reported TAVR sales of $1.2 billion, which grew 14.4% compared to the prior year, or 11.0% on a constant currency basis. SAPIEN growth in the U.S. was healthy, and it was even fa